Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.
Read original at benzingaStocks · News reference
ACADIA Pharmaceuticals shares are trading higher after Citizens and RBC Capital raised their respective price targets on the stock.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 4:49 PM
- Checked
- Aug 5, 2026, 4:49 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.
Read original at benzingaCitigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.
Read original at benzingaEuropean Commission Approves Acadia’s DAYBU For Rett Syndrome Patients Aged Five And Older Following Successful Phase 3 LAVENDER Study
Read original at benzinga